BGB-A445
BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC) . BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the research of cancer, such as colon adenocarcinoma[1][2].
Product Specifications
CAS Number
3033874-57-3
UNSPSC
12352203
Target
NF-κB; Orexin Receptor (OX Receptor)
Related Pathways
GPCR/G Protein; Neuronal Signaling; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Jiang B, et al. BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Front Med. 2023 Dec;17 (6) :1170-1185.|[2]Jiang B, et al. A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PH40684M5 20 µg
GMF beta (GMFB) (NM_004124) Human Recombinant Protein
Sign In for Pricing
View Details